Logo image of ALGS

ALIGOS THERAPEUTICS INC (ALGS) Stock Fundamental Analysis

NASDAQ:ALGS - Nasdaq - US01626L2043 - Common Stock - Currency: USD

5.5  -0.17 (-3%)

Fundamental Rating

2

ALGS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 562 industry peers in the Biotechnology industry. ALGS may be in some trouble as it scores bad on both profitability and health. ALGS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALGS has reported negative net income.
ALGS had a negative operating cash flow in the past year.
In the past 5 years ALGS always reported negative net income.
In the past 5 years ALGS always reported negative operating cash flow.
ALGS Yearly Net Income VS EBIT VS OCF VS FCFALGS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

ALGS has a worse Return On Assets (-187.19%) than 88.59% of its industry peers.
Industry RankSector Rank
ROA -187.19%
ROE N/A
ROIC N/A
ROA(3y)-103.51%
ROA(5y)-81.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALGS Yearly ROA, ROE, ROICALGS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALGS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALGS Yearly Profit, Operating, Gross MarginsALGS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

ALGS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALGS has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALGS has less shares outstanding
ALGS has a worse debt/assets ratio than last year.
ALGS Yearly Shares OutstandingALGS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ALGS Yearly Total Debt VS Total AssetsALGS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -15.39, we must say that ALGS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -15.39, ALGS is doing worse than 81.46% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -15.39
ROIC/WACCN/A
WACC10.01%
ALGS Yearly LT Debt VS Equity VS FCFALGS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

ALGS has a Current Ratio of 2.86. This indicates that ALGS is financially healthy and has no problem in meeting its short term obligations.
ALGS has a Current ratio of 2.86. This is in the lower half of the industry: ALGS underperforms 66.67% of its industry peers.
A Quick Ratio of 2.86 indicates that ALGS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.86, ALGS is doing worse than 65.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.86
Quick Ratio 2.86
ALGS Yearly Current Assets VS Current LiabilitesALGS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 75.69% over the past year.
The Revenue for ALGS has decreased by -74.60% in the past year. This is quite bad
Measured over the past years, ALGS shows a decrease in Revenue. The Revenue has been decreasing by -3.28% on average per year.
EPS 1Y (TTM)75.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.64%
Revenue 1Y (TTM)-74.6%
Revenue growth 3Y-3.28%
Revenue growth 5YN/A
Sales Q2Q%-68.46%

3.2 Future

Based on estimates for the next years, ALGS will show a very strong growth in Earnings Per Share. The EPS will grow by 28.37% on average per year.
The Revenue is expected to grow by 132.86% on average over the next years. This is a very strong growth
EPS Next Y11.33%
EPS Next 2Y2.26%
EPS Next 3Y-24.2%
EPS Next 5Y28.37%
Revenue Next Year-42.46%
Revenue Next 2Y-26.92%
Revenue Next 3Y-25.99%
Revenue Next 5Y132.86%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALGS Yearly Revenue VS EstimatesALGS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2028 2029 2030 2031 2032 500M 1B 1.5B
ALGS Yearly EPS VS EstimatesALGS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 50 -50 100 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALGS. In the last year negative earnings were reported.
Also next year ALGS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALGS Price Earnings VS Forward Price EarningsALGS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALGS Per share dataALGS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

A cheap valuation may be justified as ALGS's earnings are expected to decrease with -24.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.26%
EPS Next 3Y-24.2%

More info and screens

0

5. Dividend

5.1 Amount

ALGS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALIGOS THERAPEUTICS INC

NASDAQ:ALGS (5/23/2025, 9:12:50 PM)

5.5

-0.17 (-3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-04 2025-08-04/amc
Inst Owners46.76%
Inst Owner Change-26.43%
Ins Owners3.32%
Ins Owner Change0%
Market Cap33.60M
Analysts84.44
Price Target103.7 (1785.45%)
Short Float %17.78%
Short Ratio5.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-36.53%
Min EPS beat(2)-39.56%
Max EPS beat(2)-33.51%
EPS beat(4)1
Avg EPS beat(4)8.25%
Min EPS beat(4)-39.56%
Max EPS beat(4)119.61%
EPS beat(8)4
Avg EPS beat(8)9.53%
EPS beat(12)6
Avg EPS beat(12)9.47%
EPS beat(16)9
Avg EPS beat(16)8.6%
Revenue beat(2)2
Avg Revenue beat(2)157.77%
Min Revenue beat(2)42.31%
Max Revenue beat(2)273.24%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)50.62%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.97%
EPS NY rev (1m)-12.12%
EPS NY rev (3m)18.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-91.82%
Revenue NY rev (3m)61.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.52
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.78
EYN/A
EPS(NY)-10.66
Fwd EYN/A
FCF(TTM)-13.24
FCFYN/A
OCF(TTM)-13.21
OCFYN/A
SpS0.65
BVpS-4.74
TBVpS-4.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -187.19%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-103.51%
ROA(5y)-81.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.66%
Cap/Sales 3.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.86
Quick Ratio 2.86
Altman-Z -15.39
F-Score1
WACC10.01%
ROIC/WACCN/A
Cap/Depr(3y)18.19%
Cap/Depr(5y)31.84%
Cap/Sales(3y)3.39%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.64%
EPS Next Y11.33%
EPS Next 2Y2.26%
EPS Next 3Y-24.2%
EPS Next 5Y28.37%
Revenue 1Y (TTM)-74.6%
Revenue growth 3Y-3.28%
Revenue growth 5YN/A
Sales Q2Q%-68.46%
Revenue Next Year-42.46%
Revenue Next 2Y-26.92%
Revenue Next 3Y-25.99%
Revenue Next 5Y132.86%
EBIT growth 1Y-4.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-2.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.21%
OCF growth 3YN/A
OCF growth 5YN/A